D-0471-2026 Class II Ongoing

Recalled by PAYLESS COMPOUNDERS, LLC — Beaverton, OR

FDA drug recall D-0471-2026 was initiated by PAYLESS COMPOUNDERS, LLC on Mar 6, 2026 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 91 vials.

Recall details

Product Type
Drugs
Report Date
Apr 22, 2026
Initiation Date
Mar 6, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
91 vials

Product description

Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

OR

Code information

Lot Number 01-27-2026@14S.5

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0471-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0471-2026. Report a data issue: hello@regdatalab.com.